Crohn’s disease complicated with a bladder-fistula – a case report
DOI:
https://doi.org/10.15584/ejcem.2021.1.10Keywords:
bladder-fistula, colonoscopy, Crohn diseaseAbstract
Introduction. Entero-bladder fistula (fistula entero-vesicalis) is a pathological connection between the lumen of the gastrointestinal tract and the bladder. Entero-bladder fistulas are not a common condition. The main reason for the formation of entero-bladder fistulas are intestinal diseases occurring within the intestinal loop adjacent to the bladder resulting in the formation of an abnormal channel, the connection between the above structures
Aim. The aim is to present the causes of the fistulas can be divided into congenital and acquired (intestinal infection, cancer, Crohn’s disease, resulting from trauma and iatrogenic). Clinical manifestations of the biliary-bullous fistulae may be from the digestive or urinary tract. The most characteristic ailments are pneumaturia, fecuria, urge to urinate, frequent urination, lower abdominal pain, hematuria, urinary tract infection.
Description of the case. The article discusses the case of a patient with Leśniowski-Crohn disease complicated with a bladder-fistula. The treatment of entero-bladder fistulas is primarily surgical, it consists in resection of the fistula together with resection of the affected intestine and bladder wall fragment.
Conclusion. The test confirming the presence of an entero-bladder fistula is a test with oral administration of poppies, although it happens that the test result may be negative, especially in the case of a bladder-follicular fistula. Among the tests useful in the diagnosis of entero-bladder fistula include abdominal ultrasound, computed tomography, magnetic resonance imaging, endoscopic tests (colonoscopy or cystoscopy).
Downloads
References
Li C, Kuemmerle JF. The fate of myofibroblasts during the development of fibrosis in Crohn's Disease. J Dig Dis. 2020; 21(6):326-331.
Meng J, Huang S, Sun C, et al. Comparison of Three Magnetization Transfer Ratio Parameters for Assessment of Intestinal Fibrosis in Patients with Crohn's Disease. Korean J Radiol. 2020; 21(3):290-297.
Zhang J, Xu M, Zhou W, et al. Deficiency in the anti-apoptotic protein DJ-1 promotes intestinal epithelial cell apoptosis and aggravates inflammatory bowel disease via p53. J Biol Chem. 2020;295(13):4237-4251.
Ormsby MJ, Johnson SA, Carpena N, et al. Propionic Acid Promotes the Virulent Phenotype of Crohn's Disease-Associated Adherent-Invasive Escherichia coli. Cell Rep. 2020;30(7):2297-2305.
Niv Y. Hospitalization of Patients with Crohn's Disease: A Systematic Review and Meta-analysis. Isr Med Assoc J. 2020;22(2):111-115.
Zhu F, Li Y, Guo Z, et al. Nomogram to Predict Postoperative Intra-abdominal Septic Complications After Bowel Resection and Primary Anastomosis for Crohn's Disease. Dis Colon Rectum. 2020;63(5):629-638.
Ouraghi A, Houmaidi AE, Mhanna T, Irzi M, Alaoui WM, Barki A. Enterovesical fistula secondary to transitional cell carcinoma of the bladder in a 20 years old patient: A rare entity. Urol Case Rep. 2020;30:101123.
Kolacek M, Paduchova Z, Dvorakova M, et al. Effect of natural polyphenols on thromboxane levels in children with Crohn's disease. Bratisl Lek Listy. 2019;120(12):924-928.
Erős A, Farkas N, Hegyi P, et al. Anti-TNFα agents are the best choice in preventing postoperative Crohn's disease: A meta-analysis. Dig Liver Dis. 2019; 51(8):1086-1095
Christerson U, Keita ÅV, Winberg ME, Söderholm JD, Gustafson-Svärd C. Possible Involvement of Intracellular Calcium-Independent Phospholipase A2 in the Release of Secretory Phospholipases from Mast Cells-Increased Expression in Ileal Mast Cells of Crohn's Disease. Cells. 2019;8(7):672.
Tomioka A, Shimizu T, Asakuma M, et al. Duodenal obstruction due to chronic pancreatitis of the pancreas tail treated by surgical intervention: A case report. Medicine (Baltimore). 2019;98(27):e15856.
Krok KL, Lichtenstein GR. Nutrition in Crohn disease. Curr Opin Gastroenterol. 2003;19(2):148-153.
Oshitani N, Watanabe K, Nakamura S, Fujiwara Y, Higuchi K, Arakawa T. Dislocation of tight junction proteins without F-actin disruption in inactive Crohn's disease. Int J Mol Med. 2005;15(3):407-410.
Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr. 2005;40(2):220-222.
Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science. 2005;307(5710):734-738
Hollenbach E, Vieth M, Roessner A, Neumann M, Malfertheiner P, Naumann M. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem. 2005;280(15):14981-14988.
Annese V, Piepoli A, Latiano A, et al. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis Colon Rectum. 2005;48(1):57-64
Keroack M. Video capsule endoscopy. Curr Opin Gastroenterol. 2004 Sep;20(5):474-81.
Asimakopoulos G. Pregnancy and inflammatory bowel disease. Rev Med Chir Soc Med Nat Iasi. 2004;108(1):46-50.
Hugot JP. PPAR and Crohn's disease: another piece of the puzzle? Gastroenterology. 2005;128(2):500.
Sugawara K, Olson TS, Moskaluk CA, et al. Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology. 2005;128(2):351-360.
Grossman CJ, Hydo LJ, Wang JC, Pochapin M, Barie PS. Devastating presentations of regional enteritis (Crohn's disease): two reports of survival following severe multiple organ dysfunction syndrome. Surg Infect (Larchmt). 2004;5(3):301-307.
Barratt HS, Kalantzis C, Polymeros D, Forbes A. Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status. Aliment PharmacolTher. 2005;21(2):141-147.
Jacobstein DA, Baldassano RN. Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: balance. Inflamm Bowel Dis. 2005;11(2):203-205.
Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(3):554-558.
Mishra V, Daniel RC, Elmets CA, Levin A, Elewski BE. Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in a patient receiving adalimumab therapy. J Drugs Dermatol. 2013;12(1):16-27.
Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11(8):975-81.e1-4.
Gutiérrez A, Scharl M, Sempere L, et al. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut. 2014 ;63(2):272-280.
Denis MA, Cosyns JP, Persu A, et al. Control of AA amyloidosis complicating Crohn's disease: a clinico-pathological study. Eur J Clin Invest. 2013;43(3):292-301.
Sattianayagam PT, Gillmore JD, Pinney JH, et al. Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci. 2013;58(6):1689-1697.
Glas J, Seiderer J, Bues S, et al. IRGM variants and susceptibility to inflammatory bowel disease in the German population. PLoS One. 2013;8(1):e54338.
Brand S. Moving the genetics of inflammatory bowel diseases from bench to bedside: first steps towards personalised medicine. Gut. 2013;62(11):1531-1533.
Quencer KB, Nimkin K, Mino-Kenudson M, Gee MS. Detecting active inflammation and fibrosis in pediatric Crohn's disease: prospective evaluation of MR-E and CT-E. Abdom Imaging. 2013;38(4):705-713.
van Langenberg DR. Maintaining muscle strength in Crohn's disease: can a vitamin D daily keep muscle loss away? Dig Dis Sci. 2013;58(2):293
Roberts CL, Rushworth SL, Richman E, Rhodes JM. Hypothesis: Increased consumption of emulsifiers as an explanation for the rising incidence of Crohn's disease. J Crohns Colitis. 2013;7(4):338-341.
Moroi R, Endo K, Kinouchi Y, et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics. 2013;65(4):265-271.
Lee Y, Li H, Li J, et al. Network models of genome-wide association studies uncover the topological centrality of protein interactions in complex diseases. J Am Med Inform Assoc. 2013;20(4):619-629.
Jang YW, Park YS, Kim SH, et al. A case of Crohn's disease having normal delivery after infliximab treatment during early pregnancy. Korean J Gastroenterol. 2013;61(1):37-41
Ma C, Evaschesen CJ, Gracias G, et al. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study. Can J Gastroenterol Hepatol. 2015;29(6):309-314.
Munir H, McGettrick HM. Mesenchymal Stem Cell Therapy for Autoimmune Disease: Risks and Rewards. Stem Cells Dev. 2015;24(18):2091-2100
Plumb AA, Menys A, Russo E, et al. Magnetic resonance imaging-quantified small bowel motility is a sensitive marker of response to medical therapy in Crohn's disease. Aliment Pharmacol Ther. 2015;42(3):343-355.
Chanson P, Pariente A. Adapting the dose to the residual concentration of infliximab in cryptogenic inflammatory diseases of the intestines. Rev Prat. 2015;65(4):47
Funayama Y, Suzuki H, Takahashi K, et al. Surgical management of intestinal Crohn's disease. Nihon Geka Gakkai Zasshi. 2015;116(2):94-98.
Verma R, Walia R, Sondike SB, Khan R. Pulmonary nocardiosis in an adolescent patient with Crohn's disease treated with infliximab: a serious complication of TNF-alpha blockers. W V Med J. 2015;111(3):36-39.
Carpio D, Barreiro-de Acosta M, Echarri A, et al. Influence of urban/rural and coastal/inland environment on the prevalence, phenotype, and clinical course of inflammatory bowel disease patients from northwest of Spain: a cross-sectional study. Eur J Gastroenterol Hepatol. 2015; 27(9):1030-1037.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
